MedPath

The Analgesia Effect of Electroacupuncture Battlefield Acupuncture Versus Sham Electroakupuncture Post Surgery

Not Applicable
Not yet recruiting
Conditions
Percutaneous Nephrolithotomy
Registration Number
NCT06783556
Lead Sponsor
Indonesia University
Brief Summary

The goal of this clinical trial is to learn the effect of ear electroacupuncture BFA therapy in reducing pain, analgesic dose, and improving patient quality of live post percutaneous nephrolithotomy surgery. The main questions it aims to answer are:

* Does BFA ear electroacupuncture reduce postoperative pain of percutaneous nephrolithotomy surgery better than sham electroacupuncture group?

* Does BFA ear electroacupuncture reduce postoperative analgesic dose of percutaneous nephrolithotomy surgery better than sham electroacupuncture group?

* Does BFA ear electroacupuncture improve postoperative quality of life of percutaneous nephrolithotomy surgery better than sham electroacupuncture group?

Researchers will compare ear electroacupuncture BFA to sham electroacupuncture to see the different analgesia effect between these groups.

Participants will:

* Get ear electroacupuncture BFA or sham electroacupuncture therapy, 2 hours before surgery for 30 minutes

* Take drug paracetamol 1000 mg intravenous after surgery according to the needs of the patient's pain complaints after surgery in both groups

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Men or women aged 18-65 years
  • Patients who have been diagnosed with kidney stones measuring > 2 cm and will undergo PCNL surgery
  • VAS score <7, assessed 2 hours before PCNL surgery
  • Receive standard analgesic therapy
  • Willing to participate in this study until completion and sign an informed consent.
Exclusion Criteria
  • Kidney anatomical abnormalities
  • Ear deformities (microtia)
  • Patients with cognitive impairment, uncooperative (receiving antidepressants or strong opioid or narcotic analgesics)
  • Tumors, wounds or skin infections in the needling area.
  • Heart rhythm disorder, unstable hemodynamics that require intensive care including extremely high body temperature and using a pacemaker.
  • Allergy to acupuncture needles or certain metals
  • Patients who have had a DJ stent or nephrostomy before PCNL
  • History of metal implants in the body except amalgam

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Primary Outcome Measures
NameTimeMethod
Visual Analogue ScaleBefore therapy, minute 0, hour 8, hour 24, hour 48

Visual Analogue Scale is the tool that measures pain intensity. It use a scale with a minimum range of 0 and a maximum of 10, where 0 indicates no pain and 10 indicates the worst pain. Higher scores indicate worse pain.

Secondary Outcome Measures
NameTimeMethod
Analgesic dose reductionhour 8, hour 24, hour 48

Paracetamol 1000 mg IV is given to patient with a maximum of 3 times administration per 24 hours. The dose of paracetamol can be reduced when the patien's pain score of Visual Analogue Score is less than 3. Measurements were made by measuring the cumulative dose of analgesics after acupuncture therapy. Then compared between the two groups, which group had a greater decrease in analgesic dose.

Short Form 36 (SF-36) QuestionnaireBefore therapy, day 7

The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.

Adverse effectsDay 7

Record the adverse effects that occur after acupuncture therapy. It will be monitored for 7 days after therapy and recorded on the 7th day by assessor.

Trial Locations

Locations (1)

Universitas Indonesia

🇮🇩

Jakarta Pusat, Dki Jakarta, Indonesia

© Copyright 2025. All Rights Reserved by MedPath